Oral Session 3-10B CML: Clinical Study (2)

[OS3-10B-2] The 2G-TKIs can overcome poor prognosis of CML patients with ACAs: the New TARGET study 1

Tomoko Yoshioka¹, Naoto Takahashi¹, Masahiro Kizaki², Tatsuya Kawaguchi³, Ritsuro Suzuki⁴, Kazuhito Yamamoto⁵, Kazunori Ohnishi⁶, Tomoki Naoe⁷, Itaru Matsumura⁸ (1.Hematol., Nephrol., and Rheumatol., Akita Univ., Akita, Japan, 2.Hematol., Saitama Medical Center, Saitama Medical Univ., Saitama, Japan, 3.Medical Technol., Kumamoto Health Science Univ., Kumamoto, Japan, 4.Oncol. and Hematol., Shimane Univ. Hospital, Izumo, Japan, 5.Hematol. and Cell Therapy, Aichi Cancer Center, Nagoya, Japan, 6.Tokai-Hokuriku Block Blood Center, Seto, Japan, 7.Nagoya Medical Center, Nagoya, Japan, 8.Hematol. and Rheumatol., Kindai Univ., Osaka-Sayama, Japan)